- Home
- MYNZ vs XRTX Comparison
MYNZ vs XRTX Comparison
Compare MYNZ & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- XRTX
- Stock Information
- Founded
- MYNZ 2021
- XRTX 2011
- Country
- MYNZ Germany
- XRTX Canada
- Employees
- MYNZ N/A
- XRTX N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- MYNZ Health Care
- XRTX Health Care
- Exchange
- MYNZ Nasdaq
- XRTX Nasdaq
- Market Cap
- MYNZ 6.1M
- XRTX 5.0M
- IPO Year
- MYNZ 2021
- XRTX N/A
- Fundamental
- Price
- MYNZ $0.24
- XRTX $1.33
- Analyst Decision
- MYNZ Buy
- XRTX Strong Buy
- Analyst Count
- MYNZ 2
- XRTX 1
- Target Price
- MYNZ $3.00
- XRTX $14.00
- AVG Volume (30 Days)
- MYNZ 5.2M
- XRTX 22.7K
- Earning Date
- MYNZ 11-26-2024
- XRTX 11-29-2024
- Dividend Yield
- MYNZ N/A
- XRTX N/A
- EPS Growth
- MYNZ N/A
- XRTX N/A
- EPS
- MYNZ N/A
- XRTX N/A
- Revenue
- MYNZ $917,203.00
- XRTX N/A
- Revenue This Year
- MYNZ $36.69
- XRTX N/A
- Revenue Next Year
- MYNZ $91.67
- XRTX N/A
- P/E Ratio
- MYNZ N/A
- XRTX N/A
- Revenue Growth
- MYNZ 16.23
- XRTX N/A
- 52 Week Low
- MYNZ $0.19
- XRTX $1.09
- 52 Week High
- MYNZ $1.79
- XRTX $7.00
- Technical
- Relative Strength Index (RSI)
- MYNZ 45.71
- XRTX 41.92
- Support Level
- MYNZ $0.22
- XRTX $1.29
- Resistance Level
- MYNZ $0.36
- XRTX $1.42
- Average True Range (ATR)
- MYNZ 0.04
- XRTX 0.15
- MACD
- MYNZ 0.00
- XRTX -0.01
- Stochastic Oscillator
- MYNZ 18.59
- XRTX 18.75
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.